For the quarter ending 2025-09-30, KROS has $742,783K in assets. $39,203K in debts. $693,472K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 693,472 | 690,215 | ||
| Accounts receivable | 3,492 | 15,816 | ||
| Prepaid expenses and other current assets | 22,343 | 26,777 | ||
| Total current assets | 719,307 | 732,808 | ||
| Operating lease right-of-use assets | 17,463 | 18,072 | ||
| Property and equipment, net | 4,564 | 4,836 | ||
| Restricted cash | 1,449 | 1,449 | ||
| Other long-term assets | 0 | 0 | ||
| Total assets | 742,783 | 757,165 | ||
| Accounts payable | 2,298 | 5,267 | ||
| Current portion of operating lease liabilities | 2,318 | 2,230 | ||
| Deferred revenue | 155 | 925 | ||
| Current tax liability | 4,147 | 6,321 | ||
| Accrued expenses and other current liabilities | 15,174 | 19,964 | ||
| Total current liabilities | 24,092 | 34,707 | ||
| Operating lease liabilities, net of current portion | 15,111 | 15,724 | ||
| Total liabilities | 39,203 | 50,431 | ||
| Common stock, par value of 0.0001 per share 200,000,000 shares authorized as of september30, 2025 and december31, 2024 40,632,164 and 40,554,705 shares issued and outstanding as of september30, 2025 and december31, 2024, respectively | 4 | 4 | ||
| Additional paid-in capital | 1,161,880 | 1,157,754 | ||
| Accumulated deficit | -458,304 | -451,024 | ||
| Total stockholders' equity | 703,580 | 706,734 | ||
| Total liabilities and stockholders' equity | 742,783 | 757,165 | ||
Keros Therapeutics, Inc. (KROS)
Keros Therapeutics, Inc. (KROS)